Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. (NASDAQ: OABI) news covers developments in its antibody and peptide discovery technologies, partner collaborations, and financial performance. As a licensor of discovery research platforms to pharmaceutical and biotech companies and academic institutions, OmniAb regularly issues updates on how its technologies are being applied in drug discovery programs and on its own corporate activities.
News about OmniAb often highlights advances in its proprietary transgenic animal platforms and related tools. Recent announcements have described the launch of OmniUltra™, a transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, which OmniAb characterizes as extending into the peptide space and enabling applications such as bispecifics, multispecifics, CAR-T, radioligands, and peptide therapeutics. The company has also reported on xPloration®, a high-throughput single B-cell screening instrument that leverages machine learning and artificial intelligence for deep antibody mining.
Investors following OABI can expect news items on technology license and services agreements with partners, including arrangements that may provide service revenue, milestones, royalties, and in some cases potential equity. OmniAb’s press releases also summarize partner program milestones, such as clinical trial updates and regulatory progress for OmniAb-derived antibodies, bispecifics, antibody-drug conjugates, and other biologic modalities.
In addition, OmniAb issues periodic financial results and business highlights, including revenue composition across license, milestone, service, xPloration, and royalty streams, as well as information on private placements and guidance ranges. Conference participation, investor events, and scientific presentations at industry meetings are also frequent topics. For readers tracking OmniAb news, this mix of technology, partnership, clinical, and financial updates provides insight into how the company’s platforms are being used across the therapeutic discovery landscape.
OmniAb, Inc. (NASDAQ: OABI) announced its participation in five investor conferences throughout May 2023. Highlights include:
- H.C. Wainwright BioConnect Investor Conference on May 2, 2023, featuring a fireside chat at 9:30 a.m. ET and one-on-one meetings in New York City.
- E.F. Hutton Global Conference on May 10-11, 2023, with one-on-one meetings on May 11 at The Plaza Hotel, New York City.
- Benchmark 3rd Annual Virtual Healthcare House Call on May 23, 2023, hosting virtual one-on-one meetings.
- B. Riley Securities 23rd Annual Institutional Investor Conference on May 24-25, 2023, with meetings on May 24 in Beverly Hills.
- Craig-Hallum 20th Annual Institutional Investor Conference on May 31, 2023, at The Depot Renaissance Minneapolis Hotel.
OmniAb's platform supports pharmaceutical partners in discovering next-generation therapeutics via diverse antibody repertoires.
FAQ
What is the current stock price of OmniAb (OABI)?
What is the market cap of OmniAb (OABI)?
